Frequent deletion (31–38%) and promoter methylation (34–36%) of SH3GL2 has been reported in breast and lung carcinoma [23], [24] and also deletion in pituitary adenoma, neuroblastoma and pilocytic astrocytoma [25], [26], [27]. The gene discussed is SH3GL2; the disease is lung carcinoma.